Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
-
REGULATORY Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
-
TRENDS Top 10 PHARMA JAPAN Articles of 2024
December 25, 2024
-
REGULATORY Deferred PMP Cuts Likely to Batter Stelara; 7 Drugs Subject to Rule after LOE
December 24, 2024
-
REGULATORY CEA Expansion, Higher Copay Likely to Be Included in Minister Budget Deal
December 24, 2024
-
COMMENTARY Where Do Japan Drug Makers Stand? A Comparison with Other Industries and Mega Pharma Peers
December 24, 2024
-
REGULATORY Off-Year Price Revision to Hit 53% of Listed Drugs in 2025, Down from 69%
December 23, 2024
-
REGULATORY Three Ministers Agree on Off-Year Drug Price Revision in FY2025
December 20, 2024
-
REGULATORY Japan Set to Settle Off-Year Debate with “x1.0” Threshold for PMP Meds/Generics, “x0.5” for LLPs
December 20, 2024
-
REGULATORY Japan Weighs Tweaking “x0.625” Threshold to Narrow Off-Year Revision Coverage
December 19, 2024
-
REGULATORY Japan to Add Shingles Vaccines to NIP List from FY2025, Targeting Age 65
December 19, 2024
-
ORGANIZATION JPA Calls for Improving Package Units as Pharmacies Suffer with Unsold Stocks of Pricey Meds
December 19, 2024
-
BUSINESS Jazz’s Epilepsy Drug Candidate Nearing Submission as Japan Lifts Ban on Cannabis-Derived Meds
December 18, 2024
-
REGULATORY Ruling Bloc’s Draft Budget Policy Says Off-Year Revisions Could Alter, but DPP Calls for Explicit Mention of Repeal
December 17, 2024
-
BUSINESS Takeda Sees Up to US$20 Billion Sales Potential with 6 Late-Stage Assets
December 16, 2024
-
BUSINESS Amgen Japan Marks “Significant Milestone” with Tepezza Release, Eyes More Launches
December 16, 2024
-
REGULATORY LDP’s Tamura Renews Question over Product Coverage of Off-Year Revisions
December 16, 2024
-
COMMENTARY Battle over Off-Year Price Revision Now Heading for Political Settlement
December 13, 2024
-
REGULATORY CDP OKs Bill to Scrap Off-Year Revisions, Aims for Diet Submission Soon
December 13, 2024
-
REGULATORY Hearing Leaves Chuikyo Mixed on Off-Year Scheme, Political Decision Ever More Likely
December 12, 2024
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…